tirzepatide onset Time to of AEs in patients receiving How Tirzepatide Helps Lose Weight

Guidelines recommend GLP-1 agents with proven cardiovascular benefit for patients with type 2 diabetes and atherosclerotic cardiovascular disease

Tirzepatide is not appropriate for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

IMDIAB Study Group

Among people with pre-existing SUDs, initiation of GLP-1 receptor agonists was associated with reduced risk of SUD related emergency department visits (0.69 (0.61 to 0.78), NRD 8.92 (11.59 to 6.25)), SUD related hospital admissions (0.74 (0.65 to 0.85), NRD 6.23 (8.73 to 3.74)), and SUD related mortality (0.50 (0.32 to 0.79), NRD 1.52 (2.32 to 0.72)), and drug overdose (0.61 (0.42 to 0.88), NRD 1.49 (2.43 to 0.55)) and suicidal ideation or attempt (0.75 (0.67 to 0.83), NRD 9.95 (13.14 to 6.77))